With the exception of monotherapy agents for BRCA-mutated cancers, PARP1 inhibitors can also be used as collaborators with radiotherapy/chemosensitizers, such as paclitaxel, bevacizumab and topoisomerase inhibitors in combination therapy for various cancer types. This evidence concerns the gene PARP1 and cancer.